New and developing therapies for AL amyloidosis.
Zumbo G et al. Expert Opin Pharmacother. 2016 Dec 29:1-11. doi: 10.1080/14656566.2016.1274971. [Epub ahead of print].

Pathological characteristics of fifty patients with renal amyloidosis in Sri Lanka
Dasanayaka DL et al. Ceylon Med J. 2016 Dec 30;61(4):189-190. doi: 10.4038/cmj.v61i4.8388.

Treatment of patients with Waldenström macroglobulinaemia: clinical practice guidelines from the Myeloma Foundation of Australia Medical and Scientific Advisory Group.
Talaulikar D et al. Intern Med J. 2017 Jan;47(1):35-49. doi: 10.1111/imj.13311.

Treatment of B-cell disorder improves renal outcome of patients with monoclonal gammopathy-associated C3 glomerulopathy.
Chauvet S et al. Blood. 2017 Jan 9. pii: blood-2016-08-737163. doi: 10.1182/blood-2016-08-737163. [Epub ahead of print].

The clinicopathologic characteristics of kidney diseases related to monotypic IgA deposits.
Vignon M et al. Kidney Int. 2017 Jan 6. pii: S0085-2538(16)30633-0. doi: 10.1016/j.kint.2016.10.026. [Epub ahead of print].

Solitary plasmacytoma: population-based analysis of survival trends and effect of various treatment modalities in the USA.
Thumallapally N et al. BMC Cancer. 2017 Jan 5;17(1):13. doi: 10.1186/s12885-016-3015-5.

Genome-wide association study of immunoglobulin light chain amyloidosis in three patient cohorts: comparison with myeloma.
da Silva Filho MI et al. Leukemia. 2017 Jan 13. doi: 10.1038/leu.2016.387. [Epub ahead of print].